8-K: BioCryst Reports Strong Q4 and Full Year 2024 Results, Raises 2025 Revenue Guidance

BioCryst Pharmaceuticals announces positive Q4 and full year 2024 financial results, driven by strong ORLADEYO sales, and raises its 2025 revenue guidance.

Summary

• BioCryst Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2024.
• ORLADEYO net revenue reached $124.2 million in Q4 2024, a 36.6 percent increase year-over-year, and $437.7 million for the full year, a 34.3 percent increase year-over-year.
• The company has increased its full year 2025 ORLADEYO net revenue guidance to between $535 million and $550 million.
• GAAP operating loss for the full year 2024 was $2.5 million, while non-GAAP operating profit was $62.9 million.
• BioCryst expects to approach positive EPS and positive cash flow in the second half of 2025.
• Initial clinical data from BCX17725 in Netherton syndrome and avoralstat in diabetic macular edema is expected by the end of the year.
• The company plans to submit an NDA to expand the ORLADEYO label to children with HAE aged 2 to 11 using an oral granule formulation in 2025.
• In January 2025, BioCryst received a paragraph IV notice of certification from Annora Pharma regarding a generic version of ORLADEYO.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, increased revenue guidance, and progress in pipeline development. While there are risks associated with patent challenges and market competition, the overall tone is optimistic and suggests a promising future for the company.

Positives

• Strong growth in ORLADEYO revenue, both in Q4 and full year 2024.
• Increased 2025 revenue guidance indicates continued confidence in ORLADEYO's performance.
• The company is approaching profitability, with expectations of positive EPS and cash flow in the near future.
• Advancement of pipeline programs, including BCX17725 and avoralstat, with initial data expected in 2025.
• Planned NDA submission for ORLADEYO label expansion to children with HAE.
• Favorable early signs that more Medicare patients can afford ORLADEYO due to the Inflation Reduction Act.
• High prescriber interest in ORLADEYO, with 97 percent considering prescribing it.

Negatives

• The company received a paragraph IV notice of certification from Annora Pharma regarding a generic version of ORLADEYO, which could lead to future competition.
• GAAP operating loss for the full year 2024 was $2.5 million, although the company achieved a non-GAAP operating profit.
• Cash, cash equivalents, restricted cash and investments decreased from $390.8 million as of December 31, 2023 to $342.8 million as of December 31, 2024.

Risks

• The company faces potential legal challenges to its ORLADEYO patents from generic drug manufacturers.
• The success of pipeline programs is uncertain and dependent on clinical trial outcomes.
• Regulatory approvals for label expansions and new products are not guaranteed.
• The company's ability to achieve and sustain profitability is subject to market factors and execution of operational plans.
• International expansion and commercialization efforts may face unforeseen challenges.

Future Outlook

BioCryst has increased its full year 2025 outlook for global net ORLADEYO revenue to between $535 million and $550 million and expects to approach positive EPS and positive cash flow in the second half of 2025, and to be profitable on an EPS basis, with positive cash flow, for full year 2026.

Management Comments

• Jon Stonehouse, president and chief executive officer of BioCryst, stated that 2024 was the strongest year in the company's history and that 2025 is off to a fantastic start.
• Charlie Gayer, chief commercial officer of BioCryst, noted favorable early signs that more Medicare patients are able to afford ORLADEYO due to the Inflation Reduction Act and that new prescription demand remained strong.
• Dr. Helen Thackray, chief R&D officer of BioCryst, highlighted the unmet need for an oral option for children with HAE and the progress of the company's pipeline programs.
• Anthony Doyle, chief financial officer of BioCryst, expressed confidence in achieving profitability goals, with revenue growth significantly outpacing operating expenses.

Industry Context

BioCryst's focus on oral small-molecule therapies for rare diseases aligns with a growing trend in the pharmaceutical industry towards more convenient and patient-friendly treatments. The company's success with ORLADEYO positions it as a key player in the hereditary angioedema market, competing with both established and emerging therapies.

Comparison to Industry Standards

• ORLADEYO's revenue growth of 34.3% year-over-year demonstrates strong market penetration compared to other HAE therapies.
• Competitors like Takeda (TAK) with TAKHZYRO and CSL Behring with HAEGARDA also have significant market share, but ORLADEYO's oral administration offers a distinct advantage.
• BioCryst's pipeline programs targeting Netherton syndrome and diabetic macular edema address unmet needs in rare disease markets, similar to companies like Vertex Pharmaceuticals (VRTX) that focus on cystic fibrosis.
• The company's expectation to approach positive EPS and cash flow in 2H 2025 is a key milestone compared to other biotech companies in the rare disease space, such as Alnylam Pharmaceuticals (ALNY), which are also striving for profitability.

Legal Proceedings

• The company intends to vigorously defend its intellectual property rights protecting ORLADEYO against a paragraph IV challenge from Annora Pharma.

Stakeholder Impact

• Shareholders can expect continued growth in revenue and potential for increased profitability.
• Patients with HAE may benefit from the expanded label for ORLADEYO to include children aged 2 to 11.
• Patients with Netherton syndrome and diabetic macular edema may benefit from the development of new therapies.
• Employees can expect continued investment in the company's growth and pipeline programs.

Next Steps

• Submit an NDA to the FDA for ORLADEYO label expansion to children with HAE aged 2 to 11.
• Advance BCX17725 into clinical trials and expect initial data in 2025.
• Advance avoralstat into a clinical trial for patients with diabetic macular edema in 2025.
• Continue commercialization efforts for ORLADEYO in existing and new markets.
• Vigorously defend intellectual property rights protecting ORLADEYO.

Key Dates

Keywords

ORLADEYO, BioCryst, HAE, Revenue, Financial Results, Pipeline, BCX17725, Avoralstat, Netherton Syndrome, Diabetic Macular Edema